デフォルト表紙
市場調査レポート
商品コード
1692334

動物医療向けモノクローナル抗体市場- 世界の産業規模、シェア、動向、機会、予測、動物タイプ別、用途別、エンドユーザー別、地域別、競合別、2020～2030年

Monoclonal Antibodies In Veterinary Health Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type, By Application, End-User, By Region, & Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
動物医療向けモノクローナル抗体市場- 世界の産業規模、シェア、動向、機会、予測、動物タイプ別、用途別、エンドユーザー別、地域別、競合別、2020～2030年
出版日: 2025年03月24日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

動物医療向けモノクローナル抗体の世界市場規模は2024年に9億340万米ドルとなり、2030年までのCAGRは15.50%と予測されます。

動物医療向けモノクローナル抗体（mAb）の世界市場は、広範な動物ヘルスケア産業の中で急成長している分野です。モノクローナル抗体は、特定の抗原を標的とすることができる実験室で作製された抗体であり、治療および診断用途のために獣医学で採用されることが増えています。

市場概要
予測期間 2026～2030年
市場規模：2024年 9億340万米ドル
市場規模：2030年 21億4,929万米ドル
CAGR：2025～2030年 15.50%
急成長セグメント 皮膚科
最大市場 北米

主な市場促進要因

コンパニオンアニマルの飼育増加とペットの人間化

主な市場課題

高い開発コスト

主な市場動向

標的療法の拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の動物医療向けモノクローナル抗体市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 動物タイプ別（犬、その他）
    • 用途別（皮膚科、疼痛科、その他）
    • エンドユーザー別（動物病院、その他）
    • 地域別
    • 企業別（2024年）
  • 製品市場マップ
    • 動物タイプ別
    • 用途別
    • エンドユーザー別
    • 地域別

第6章 北米の動物医療向けモノクローナル抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の動物医療向けモノクローナル抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン

第8章 アジア太平洋地域の動物医療向けモノクローナル抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国

第9章 南米の動物医療向けモノクローナル抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの動物医療向けモノクローナル抗体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収
  • 製品上市

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco LLC
  • Boehringer Ingelheim GmbH
  • Indian Immunologicals Ltd
  • Virbac SA

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 17566

Global Monoclonal Antibodies In Veterinary Health Market was valued at USD 903.40 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 15.50% through 2030. The global monoclonal antibodies (mAbs) in veterinary health market represents a rapidly growing segment within the broader animal healthcare industry. Monoclonal antibodies, which are lab-engineered antibodies that can target specific antigens, are increasingly being adopted in veterinary medicine for their therapeutic and diagnostic applications.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 903.40 Million
Market Size 2030USD 2149.29 Million
CAGR 2025-203015.50%
Fastest Growing SegmentDermatology
Largest MarketNorth America

Key Market Drivers

Increasing Companion Animal Ownership and Pet Humanization

The increasing trend of companion animal ownership, coupled with the growing humanization of pets, is a major driver of the Global Monoclonal Antibodies (mAbs) in the Veterinary Health Market. Over 50% of the global population is estimated to own a pet, with dogs being the most prevalent, found in approximately 33% of households worldwide. Cats are the second most popular choice, owned by nearly 25% of pet-keeping households. This widespread pet ownership trend reflects a significant and growing market opportunity for pet-related industries, including food, healthcare, accessories, and services, driven by increasing consumer demand and the human-animal bond. As pet owners demand higher-quality healthcare solutions for their animals, the market for advanced veterinary therapeutics, including monoclonal antibody-based treatments, is experiencing significant growth.

Households in the U.S., EU, and China collectively own over 500 million dogs and cats, underscoring a massive and expanding market for pet healthcare solutions. In the U.S., pet ownership grew from 68% of households in 2016 to 70% in 2021, reflecting a sustained upward trend in companion animal adoption and increased consumer spending on veterinary care. Over the past decade, there has been a significant increase in pet adoption rates, particularly in developed economies such as North America, Europe, and parts of Asia-Pacific. Factors such as rising disposable incomes, changing lifestyles, and a growing preference for emotional companionship have contributed to this trend. With pet ownership on the rise, there is a corresponding increase in demand for effective veterinary treatments, including monoclonal antibodies for conditions such as arthritis, dermatological disorders, and cancer.

Key Market Challenges

High Development Costs

Developing monoclonal antibodies is a complex and expensive process. Research and development costs can be prohibitively high, which poses a significant challenge for smaller biotech companies and startups looking to enter the market. These high costs can limit the diversity of players and the range of mAb products available..

Key Market Trends

Expansion of Targeted Therapies

One of the most significant upcoming trends is the expansion of targeted therapies using monoclonal antibodies. As our understanding of animal diseases and their molecular mechanisms deepens, researchers are developing mAbs that can target specific disease pathways with precision. This trend promises to provide veterinarians with a broader range of effective treatment options for a variety of conditions.

Key Market Players

  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco LLC
  • Boehringer Ingelheim GmbH
  • Indian Immunologicals Ltd
  • Virbac SA

Report Scope:

In this report, the Global Monoclonal Antibodies In Veterinary Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Monoclonal Antibodies In Veterinary Health Market, By Animal Type:

  • Dogs
  • Others

Monoclonal Antibodies In Veterinary Health Market, By Application:

  • Dermatology
  • Pain
  • Others

Monoclonal Antibodies In Veterinary Health Market, By End-User:

  • Veterinary Hospitals
  • Others

Monoclonal Antibodies In Veterinary Health Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Monoclonal Antibodies In Veterinary Health Market.

Available Customizations:

Global Monoclonal Antibodies In Veterinary Health market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monoclonal Antibodies In Veterinary Health Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Dogs, Others)
    • 5.2.2. By Application (Dermatology, Pain, Others)
    • 5.2.3. By End-User (Veterinary Hospitals, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Animal Type
    • 5.3.2. By Application
    • 5.3.3. By End-User
    • 5.3.4. By Region

6. North America Monoclonal Antibodies In Veterinary Health Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type (Dogs, Others)
    • 6.2.2. By Application (Dermatology, Pain, Others)
    • 6.2.3. By End-User (Veterinary Hospitals, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-User

7. Europe Monoclonal Antibodies In Veterinary Health Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type (Dogs, Others)
    • 7.2.2. By Application (Dermatology, Pain, Others)
    • 7.2.3. By End-User (Veterinary Hospitals, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-User
    • 7.3.2. United Kingdom Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-User
    • 7.3.3. France Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-User

8. Asia-Pacific Monoclonal Antibodies In Veterinary Health Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type (Dogs, Others)
    • 8.2.2. By Application (Dermatology, Pain, Others)
    • 8.2.3. By End-User (Veterinary Hospitals, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-User
    • 8.3.2. Japan Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-User
    • 8.3.3. India Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-User
    • 8.3.4. Australia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-User
    • 8.3.5. South Korea Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-User

9. South America Monoclonal Antibodies In Veterinary Health Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type (Dogs, Others)
    • 9.2.2. By Application (Dermatology, Pain, Others)
    • 9.2.3. By End-User (Veterinary Hospitals, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-User
    • 9.3.2. Argentina Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-User
    • 9.3.3. Colombia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-User

10. Middle East and Africa Monoclonal Antibodies In Veterinary Health Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type (Dogs, Others)
    • 10.2.2. By Application (Dermatology, Pain, Others)
    • 10.2.3. By End-User (Veterinary Hospitals, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-User
    • 10.3.2. Saudi Arabia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-User
    • 10.3.3. UAE Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-User
    • 10.3.4. Kuwait Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Animal Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Zoetis Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offering
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (as reported)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Merck & Co., Inc.
  • 14.3. Elanco LLC
  • 14.4. Boehringer Ingelheim GmbH
  • 14.5. Indian Immunologicals Ltd
  • 14.6. Virbac SA

15. Strategic Recommendations

16. About Us & Disclaimer